Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07227194 · ClinicalTrials.gov registry record
Machine Learning Assessment of Next-Day Migraine Likelihood
A clinical trial, sponsored by Theranica.
- Completed
- Registry status
- 53,065
- Enrollment target
NCT07227194: Completed study, sponsored by Theranica.
NCT07227194 is a clinical trial that has completed, run by Theranica. The registered enrollment target is 53,065 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07227194 has completed, sponsored by Theranica.
- COMPLETED
- Registry status
- 53,065 participants
- Enrollment target
Study Summary
Development of a machine learning (ML) algorithm for assessment of next-day migraine likelihood, drawing on self-reported migraine-related information, and geographic location, collected via the Nerivio app- a mobile application used for migraine treatment by the Remote Electrical Neuromodulation (REN) wearable device.
Primary Outcome
The percentage of migraine days correctly predicted, out of all predicted days.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53,065 participants |
| Start Date | 2025-02-07 |
| Est. Completion | 2025-08-20 |
What the finished NCT07227194 record still lists
NCT07227194 is an observational study that tracks outcomes without assigning an intervention. Its 53,065 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT07227194 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07227194 about?
NCT07227194 is a clinical study titled "Machine Learning Assessment of Next-Day Migraine Likelihood". Development of a machine learning (ML) algorithm for assessment of next-day migraine likelihood, drawing on self-reported migraine-related information, and geographic location, collected via the Nerivio app- a mobile application used for migraine treatment by the Remote Electrical Neuromodulation (R...
What is the current status of trial NCT07227194?
This trial is currently completed. The enrollment target is 53,065 participants. The study started on 2025-02-07. Estimated completion is 2025-08-20.
Who is sponsoring clinical trial NCT07227194?
This trial is sponsored by Theranica, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05975671 · 52,500 participants · NA
Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis
- NCT07224243 · 54,000 participants · NA
Impact of Intraoperative Oxygenation Practices on Patient Outcomes
- NCT06355934 · 52,121 participants
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
- NCT00500123 · 50,000 participants
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI